The legislation championed by Kamala Harris allows Medicare to negotiate drug prices, a shift that marks a significant change in the political landscape of pharmaceutical pricing.
Trump's first term saw various fragmented proposals aimed at reducing prescription costs; however, the lack of cohesive strategy weakened their overall impact.
The changing political environment sees the drug industry, once seen as untouchable, now under pressure from both parties to address rising drug prices.
Pharmaceutical companies are shifting their campaign contributions, moving from a predominantly Republican focus to a more balanced approach due to increasing scrutiny and public dissatisfaction.
Collection
[
|
...
]